Print this page    •   Back to Web version of article

Isentress (Raltegravir) Pricing: Community Sign-On Letter

October 11, 2007

Summary: The Fair Pricing Coalition and others are collecting signatures until this important Merck drug (the first integrase inhibitor) is approved and launched.

The Fair Pricing Coalition is asking Merck to price its new and very important integrase inhibitor at a level everyone can live with. The letter is seeking organization and individual signers until the official launch of the drug, when the price will be announced.

"A new HIV drug produced by Merck is about to be approved by the Food & Drug Administration in early October. While this is great news, especially for people who have developed resistance to existing therapies, the pricing of this treatment will have a major impact on the various publicly funded programs like Medicaid, Medicare, and the AIDS Drug Assistance Program, all of which are already straining at the breaking point.

"Please join the Fair Pricing Coalition by signing onto the following statement to Merck. ..."

For the text of the letter and instructions for signing, click here.




This article was provided by AIDS Treatment News. It is a part of the publication AIDS Treatment News. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/treat/art43530.html

General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.